COMMUNIQUÉS West-GlobeNewswire

Entourage Health Reports First Quarter 2024 Financial Results: Achieves $16.4 Million in Total Revenue and Marks First EBITDA-Positive Quarter
28/05/2024
Entourage's solid financial performance entering 2024 underscores its positive trajectory and positions the Company for continued success in upcoming quarters Total revenue of $16.4 million represents a 9% increase year [...]
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
28/05/2024
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data [...]
Affimed Announces Annual General Meeting of Shareholders
28/05/2024
MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
28/05/2024
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours
28/05/2024
28 MAY 2024 PRESS RELEASE Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock Exchange: URT) biotechnology [...]
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
28/05/2024
LA JOLLA, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
28/05/2024
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
28/05/2024
Results reinforce potential to develop TILT-123 as a systemic therapy HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer [...]
Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress
28/05/2024
Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress LoAc® compound lowers renal cAMP after single or multiple doses and demonstrates efficacy in a preclinical model of [...]
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
28/05/2024
PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 [...]
Descriptif du cadre réglementaire du programme de rachat d’actions soumis par le Conseil d’administration à l’approbation de l’Assemblée Générale Annuelle des actionnaires d’Ipsen S.A. du 28 mai 2024
28/05/2024
PARIS, FRANCE, 28 mai 2024 - Conformément aux dispositions de l’article L.22-10-62 et suivants du Code de commerce, du Règlement européen n°596/2014 du 16 avril 2014 du Parlement européen et du Conseil, du Règlement [...]
Santhera Publishes Agenda for its Annual General Meeting
28/05/2024
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on June 18, [...]
Santhera Publishes Annual Report 2023
28/05/2024
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2023 with fully audited results for the year ended [...]
Large Protests This Week Across Ontario in Response to Ford Government’s Health Care Privatization & Closures of Local Hospitals
27/05/2024
TORONTO, May 27, 2024 (GLOBE NEWSWIRE) -- Raising the alarm about the urgent threat to public health care, the Ontario Health Coalition is mobilizing thousands of Ontarians to fightback against the Ford government’s [...]
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
27/05/2024
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024
27/05/2024
NEW YORK, 27 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
27/05/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 27, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2024
27/05/2024
Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024
27/05/2024
Nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Charenton- [...]

Pages